Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc.verified

NRIX

Price:

$22.05

Market Cap:

$1.56B

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell th...[Read more]

Industry

Biotechnology

IPO Date

2020-07-24

Stock Exchange

NASDAQ

Ticker

NRIX

The PE Ratio as of November 2024 (TTM) for Nurix Therapeutics, Inc. (NRIX) is -7.60

According to Nurix Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -7.60. This represents a change of 44.84% compared to the average of -5.25 of the last 4 quarters.

Nurix Therapeutics, Inc. (NRIX) Historical PE Ratio (quarterly & annually)

How has NRIX PE Ratio performed in the past?

The mean historical PE Ratio of Nurix Therapeutics, Inc. over the last ten years is -16.41. The current -7.60 PE Ratio has changed 4.53% with respect to the historical average. Over the past ten years (40 quarters), NRIX's PE Ratio was at its highest in in the May 2020 quarter at 21.84. The PE Ratio was at its lowest in in the August 2019 quarter at -40.69.

Quarterly (TTM)
Annual

Average

-16.41

Median

-13.00

Minimum

-34.03

Maximum

-2.35

Nurix Therapeutics, Inc. (NRIX) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Nurix Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 4.79%

Maximum Annual PE Ratio = -2.35

Minimum Annual Increase = -65.62%

Minimum Annual PE Ratio = -34.03

Quarterly (TTM)
Annual
YearPE RatioChange
2023-2.35-35.27%
2022-3.63-65.62%
2021-10.55-31.71%
2020-15.45-54.61%
2019-34.034.79%

Nurix Therapeutics, Inc. (NRIX) Average PE Ratio

How has NRIX PE Ratio performed in the past?

The current PE Ratio of Nurix Therapeutics, Inc. (NRIX) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-5.51

5-year avg

-13.20

10-year avg

-16.41

Nurix Therapeutics, Inc. (NRIX) PE Ratio vs. Peers

How is NRIX’s PE Ratio compared to its peers?

Nurix Therapeutics, Inc.’s PE Ratio is less than Foghorn Therapeutics Inc. (-5.38), less than Shattuck Labs, Inc. (-0.69), less than Monte Rosa Therapeutics, Inc. (-5.83), greater than Kymera Therapeutics, Inc. (-20.45), less than C4 Therapeutics, Inc. (-2.80), less than Arvinas, Inc. (-6.04), less than Eliem Therapeutics, Inc. (-2.42), less than Prelude Therapeutics Incorporated (-0.55), less than Relay Therapeutics, Inc. (-1.93), less than Stoke Therapeutics, Inc. (-6.11), less than Pliant Therapeutics, Inc. (-3.91), less than Black Diamond Therapeutics, Inc. (-1.96), less than Nkarta, Inc. (-1.63), less than Lyell Immunopharma, Inc. (-1.19), less than Generation Bio Co. (-0.63), less than Sana Biotechnology, Inc. (-2.01),

Build a custom stock screener for Nurix Therapeutics, Inc. (NRIX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Nurix Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Nurix Therapeutics, Inc. (NRIX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Nurix Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Nurix Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for Nurix Therapeutics, Inc. (NRIX)?

What is the highest PE Ratio for Nurix Therapeutics, Inc. (NRIX)?

What is the 3-year average PE Ratio for Nurix Therapeutics, Inc. (NRIX)?

What is the 5-year average PE Ratio for Nurix Therapeutics, Inc. (NRIX)?

How does the current PE Ratio for Nurix Therapeutics, Inc. (NRIX) compare to its historical average?